Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

NCT02260544 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Epithelial Cancer Recurrent

Interventions

DRUG: Doxorubicin Hydrochloride Liposome Injection

Sponsor

Dr. Reddy's Laboratories Limited